Why the Botanix share price could crash lower on Wednesday

The Botanix Pharmaceuticals Ltd (ASX:BOT) share price looks set to crash lower on Wednesday following a disappointing study result…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It looks set to be a disappointing day of trade for the Botanix Pharmaceuticals Ltd (ASX: BOT) share price on Wednesday.

The cannabis-focused medical dermatology company's shares look set to be sold off after a disappointing study result.

What did Botanix announce?

Late on Tuesday night the company released topline data from its Phase 2 BTX 1503 study. This study was evaluating its safety and efficacy in patients with moderate to severe acne and preparations for a Phase 3 clinical program.

Expectations were high that BTX 1503 could become the new standard of care for acne sufferers, replacing existing treatment options that come with horrific side effects.

According to Botanix's release, its 12-week randomised, double blind, vehicle-controlled study enrolled 368 patients with moderate to severe acne across 35 dermatology sites in Australia and the USA.

Unfortunately, the topline data revealed that the primary endpoint (aim) of reducing inflammatory lesions did not achieve statistical significance.

And while the secondary endpoint of reducing non-inflammatory endpoints was statistically significant, the primary endpoint is the one that matters. Especially given that other promising drugs under development are also aiming to leverage the antimicrobial properties of synthetic cannabidiol in a similar way.

However, there is a glimmer of hope for Botanix and its shareholders. While its result was not statistically significance, management blamed this on an abnormally positive result from a placebo group. Discounting this, the result is potentially a positive.

Vince Ippolito, President and Executive Chairman of Botanix said: "We are pleased with the overall efficacy outcomes, clean safety profile and highly significant Australian data. We are very thankful to all of the investigators and patients who helped Botanix rapidly complete this Phase 2 study."

What now?

Management appears intent on trying to commercialise the product despite this disappointing result.

It advised that "Botanix is moving forward with its preparations for Phase 3 clinical program and planning an end-of-Phase 2 meeting with the US Food and Drug Administration."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why CBA, Inghams, Praemium, and Strike Energy shares are tumbling today

These shares are having a tough time on Tuesday. But why?

Read more »

Man with a hand on his head looks at a red stock market chart showing a falling share price.
Share Fallers

Why Brightstar, Eagers Automotive, Regis Resources, and Westpac shares are sinking

These shares are starting the week in the red. But why?

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why 29Metals, Atlas Arteria, DroneShield, and Yancoal shares are falling today

Let's see why these shares are ending the week in the red.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Fallers

Why 29Metals, CAR Group, DroneShield, and Santana Minerals shares are falling today

These shares are missing out on the good times on Thursday. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Imricor, Imugene, Newmont, and Pepper Money shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Cromwell Property, Metcash, Pilbara Minerals, and Tyro shares are falling today

Let's see why these shares are under pressure on Tuesday.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Block, Computershare, South32, and Strickland Metals shares are falling today

These shares are starting the week in the red. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Imricor, Ora Banda, Ventia, and Vulcan shares are dropping today

These shares are ending the week in the red. But why?

Read more »